您好，欢迎来到试剂仪器网！ [登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > NBD-556
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
NBD-556
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
NBD-556图片
CAS NO:333353-44-9
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
NBD-556 是一种 CD4 模拟物，是一种有效的 HIV-1 进入抑制剂，可阻断 gp120-CD4 相互作用。
Cas No.333353-44-9
别名N-(4-氯苯基)-N'-(2,2,6,6-四甲基哌啶-4-基)草酰胺,NBD 556;NBD556
化学名N'-(4-chlorophenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
Canonical SMILESCC1(CC(CC(N1)(C)C)NC(=O)C(=O)NC2=CC=C(C=C2)Cl)C
分子式C17H24ClN3O2
分子量337.84
溶解度DMF: 30 mg/mL,DMSO: 30 mg/mL,DMSO:PBS (pH 7.2) (1:1): 0.5 mg/mL,Ethanol: 10 mg/mL
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

IC50: NBD-556 inhibited cell–cell fusion between H9/HIV-1IIIB and MT-2 (IC50 ~3 μM)

The entry of HIV-1 into host cells is mediated by the binding of the surface subunit gp120 to the host cell receptor CD4. NBD-556 is a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitor that block the gp120–CD4 interaction with drug-like properties.

In vitro: A systematic study showed that NBD-556 and NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, protease, or integrase, demonstrating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-556 and NBD-557 were also active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, showing that these compounds can potentially be further modified to become potent HIV-1 entry inhibitors [1].

In vivo: No animal in-vivo data available currently.

Clinical trial: No clinical data are available.

Reference:
[1] Zhao, Q.  , L. Ma, S. Jiang, H. Lu, S. Liu, Y. He, N. Strick, N. Neamati, and A. K. Debnath. 2005. Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 339:213-225.